CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $367,068 | -21.2% | 9,747 | -0.8% | 0.39% | -16.2% |
| Q2 2023 | $465,710 | +21.9% | 9,823 | -2.2% | 0.46% | -4.9% |
| Q1 2023 | $382,086 | -15.0% | 10,044 | -23.7% | 0.49% | -21.7% |
| Q4 2022 | $449,256 | -31.7% | 13,166 | +30.8% | 0.62% | -21.8% |
| Q3 2022 | $658,000 | +10.8% | 10,068 | -13.0% | 0.80% | +14.3% |
| Q2 2022 | $594,000 | +15.1% | 11,567 | +35.9% | 0.70% | +63.2% |
| Q1 2022 | $516,000 | -3.4% | 8,511 | +16.4% | 0.43% | -1.8% |
| Q4 2021 | $534,000 | -16.3% | 7,309 | +28.2% | 0.44% | -27.5% |
| Q3 2021 | $638,000 | -17.8% | 5,701 | +19.0% | 0.60% | -21.9% |
| Q2 2021 | $776,000 | +72.4% | 4,791 | +29.6% | 0.77% | +58.4% |
| Q1 2021 | $450,000 | +67.3% | 3,697 | +110.1% | 0.48% | +77.7% |
| Q4 2020 | $269,000 | – | 1,760 | – | 0.27% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,608,874 | $160,053,562,000 | 54.44% |
| Abingworth LLP | 1,237,202 | $54,858,000 | 32.62% |
| NEA Management Company, LLC | 2,090,678 | $92,722,000 | 4.00% |
| New Leaf Venture Partners, L.L.C. | 444,708 | $19,723,000 | 3.59% |
| EcoR1 Capital, LLC | 500,000 | $22,175,000 | 2.00% |
| ARK Investment Management | 1,453,590 | $64,467,000 | 1.95% |
| CLOUGH CAPITAL PARTNERS L P | 337,731 | $14,978,000 | 1.41% |
| Casdin Capital, LLC | 220,000 | $9,757,000 | 1.19% |
| Valiant Capital Management, L.P. | 271,700 | $12,050,000 | 1.07% |
| Monashee Investment Management LLC | 110,000 | $4,879,000 | 1.03% |